DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, five have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $35.3750.

A number of research analysts have recently weighed in on DBVT shares. Weiss Ratings reissued a “sell (e+)” rating on shares of DBV Technologies in a research report on Monday, December 29th. Guggenheim reissued a “buy” rating and set a $51.00 price objective (up from $35.00) on shares of DBV Technologies in a report on Wednesday, December 17th. Cantor Fitzgerald set a $48.00 target price on DBV Technologies in a research note on Wednesday, December 17th. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a research note on Wednesday, December 17th. Finally, Wall Street Zen upgraded DBV Technologies from a “sell” rating to a “hold” rating in a research note on Sunday.

DBV Technologies Price Performance

NASDAQ DBVT opened at $22.60 on Friday. The business’s fifty day moving average is $19.95 and its 200-day moving average is $14.70. The stock has a market capitalization of $907.62 million, a price-to-earnings ratio of -4.37 and a beta of -0.98. DBV Technologies has a one year low of $3.82 and a one year high of $26.18.

Insider Activity

In other news, major shareholder Bpifrance Epic sold 1,292,103 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $4.19, for a total value of $5,413,911.57. Following the sale, the insider owned 7,303,369 shares of the company’s stock, valued at $30,601,116.11. The trade was a 15.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 3,369,627 shares of company stock valued at $15,489,908 over the last 90 days. Insiders own 1.44% of the company’s stock.

Institutional Investors Weigh In On DBV Technologies

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Allworth Financial LP bought a new position in shares of DBV Technologies in the fourth quarter worth $32,000. New York State Common Retirement Fund bought a new position in shares of DBV Technologies in the third quarter worth $34,000. GAMMA Investing LLC raised its position in shares of DBV Technologies by 38.4% in the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after buying an additional 744 shares in the last quarter. Two Sigma Investments LP bought a new stake in DBV Technologies during the third quarter valued at $167,000. Finally, Citadel Advisors LLC bought a new stake in DBV Technologies during the third quarter valued at $220,000. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.